As filed with the Securities and Exchange Commission on August 8, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
Form S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
_______________________________
Syndax Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
_______________________________
|
Delaware |
32-0162505 |
|
(State or other jurisdiction of incorporation or organization) |
(IRS employer identification number) |
35 Gatehouse Drive
Building D, Floor 3
Waltham, Massachusetts 02451
(781) 419-1400
(Address of principal executive offices)
_______________________________
2015 Omnibus Incentive Plan
2015 Employee Stock Purchase Plan
(Full titles of the plans)
_______________________________
Briggs W. Morrison, M.D.
Chief Executive Officer
Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive
Building D, Floor 3
Waltham, Massachusetts 02451
(781) 419-1400
(Name, address and telephone number of agent for service)
|
Copies to: |
|
|
Laura Berezin Cooley LLP 3175 Hanover Street Palo Alto, California 94304 (650) 843-5000 |
Luke J. Albrecht Vice President, General Counsel & Secretary 35 Gatehouse Drive Building D, Floor 3 Waltham, Massachusetts 02451 (781) 419-1400 |
_______________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer ☐ |
Accelerated filer ☒ |
|
Non-accelerated filer ☐ (Do not check if a smaller reporting company) |
Smaller reporting company ☐ |
|
Emerging growth company ☒ |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
|
|
||||
|
Title of Securities To Be Registered |
Amount To Be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Amount of Registration Fee |
|
2015 Omnibus Incentive Plan (Common stock, $0.0001 par value per share) |
975,601 (2) |
$6.46 (4) |
$6,302,382.46 (4) |
$784.65 |
|
2015 Employee Stock Purchase Plan (Common stock, $0.0001 par value per share) |
243,900 (3) |
$6.46 (4) |
$1,575,594.00 (4) |
$196.16 |
|
|
||||
|
|
||||
|
(1) |
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock that become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of Syndax Pharmaceuticals, Inc.’s (the “Registrant”) outstanding shares of common stock. |
|
(2) |
Represents additional shares of the Registrant’s common stock reserved for future grant under the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan (the “2015 Plan”) as a result of the automatic increase in shares reserved thereunder on January 1, 2018 pursuant to the terms of the 2015 Plan. The 2015 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2015 Plan on January 1, from 2017 until the expiration of the 2015 Plan. The number of shares added each year will be equal to the lesser of: (a) 4% of the total number of shares of the Registrant’s common stock outstanding on December 31 of the preceding calendar year; and (b) the number of shares of the Registrant’s common stock designated by action of the Registrant’s board of directors prior to the first day of any calendar year. |
|
(3) |
Represents additional shares of the Registrant’s common stock reserved for issuance under the Syndax Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (the “ESPP”) as a result of the automatic increase in shares reserved thereunder on January 1, 2018 pursuant to the terms of the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1, from 2017 until the expiration of the ESPP. The number of shares added each year will be equal to the lesser of: (a) 1% of the total number of shares of the Registrant’s common stock outstanding on December 31 of the preceding calendar year; (b) 250,000 shares of the Registrant’s common stock; and (c) a number of shares of the Registrant’s common stock designated by action of the Registrant’s board of directors prior to the first day of any calendar year. |
|
(4) |
Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee. The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of the Registrant’s common stock as reported on The Nasdaq Global Select Market on August 3, 2018. |
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by References
The Registrant is filing this Registration Statement for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.
The Registrant previously registered shares of its Common Stock for issuance under the 2015 Plan and the ESPP under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (“SEC”) on March 25, 2016 (File No. 333-210412) and August 25, 2017 (File No. 333-220172). Pursuant to General Instruction E to Form S-8, this Registration Statements hereby incorporates by reference the contents of the Registration Statements referenced above.
Item 8. Exhibits
The exhibits to this Registration Statement are listed below and incorporated by reference herein.
|
Exhibit |
Exhibit Description |
|
4.1 |
|
|
4.2 |
|
|
4.3 |
|
|
4.4 |
|
|
4.5 |
|
|
4.6 |
|
|
4.7 |
|
|
5.1 |
|
|
23.1 |
|
|
23.2 |
|
|
24.1 |
Power of Attorney (included on the signature page to this Registration Statement). |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Waltham, Commonwealth of Massachusetts, on August 8, 2018.
Syndax Pharmaceuticals, Inc.
By: /s/ Briggs W. Morrison, M.D.
Briggs W. Morrison, M.D.
Chief Executive Officer
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Briggs W. Morrison, M.D. and Luke J. Albrecht, and each of them, his true and lawful attorney-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
/s/ Briggs W. Morrison, M.D. |
|
Chief Executive Officer and Director (Principal Executive Officer) |
|
August 8, 2018 |
|
Briggs W. Morrison, M.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Richard P. Shea |
|
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) |
|
August 8, 2018 |
|
Richard P. Shea |
|
|
|
|
|
|
|
|
|
|
|
/s/ Dennis G. Podlesak |
|
Chairman of the Board of Directors |
|
August 8, 2018 |
|
Dennis G. Podlesak |
|
|
|
|
|
|
|
|
|
|
|
/s/ Henry Chen |
|
Director |
|
August 8, 2018 |
|
Henry Chen |
|
|
|
|
|
|
|
|
|
|
|
/s/ Fabrice Egros, PharmD, Ph.D. |
|
Director |
|
August 8, 2018 |
|
Fabrice Egros, PharmD, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Luke Evnin, Ph.D. |
|
Director |
|
August 8, 2018 |
|
Luke Evnin, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Keith A. Katkin |
|
Director |
|
August 8, 2018 |
|
Keith A. Katkin |
|
|
|
|
|
|
|
|
|
|
|
/s/ Pierre Legault |
|
Director |
|
August 8, 2018 |
|
Pierre Legault |
|
|
|
|
Exhibit 5.1
August 8, 2018
Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive, Building D,
Floor 3
Waltham, Massachusetts 02451
Ladies and Gentlemen:
We have acted as counsel to Syndax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and you have requested our opinion in connection with the filing of a registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission covering the offering of up to 1,219,501 shares of the Company’s Common Stock, $0.0001 par value (the “Shares”), pursuant to the Company’s 2015 Omnibus Incentive Plan and 2015 Employee Stock Purchase Plan (the “Plans”).
In connection with this opinion, we have examined the Registration Statement and related prospectus, your Certificate of Incorporation, as amended and restated, and Bylaws, as amended and restated, and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters. We have assumed the genuineness and authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof, and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof. Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated.
Our opinion herein is expressed solely with respect to the General Corporation Law of the State of Delaware. Our opinion is based on those laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectus, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).
We consent to the filing of this opinion as an exhibit to the Registration Statement.
Very truly yours,
Cooley LLP
By: /s/ Laura A. Berezin
Laura A. Berezin
Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130
t: (650) 843-5000 f: (650) 849-7400 cooley.com
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 8, 2018, relating to the financial statements of Syndax Pharmaceuticals, Inc. and its subsidiaries, appearing in the Annual Report on Form 10-K of Syndax Pharmaceuticals, Inc. and its subsidiaries for the year ended December 31, 2017.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
August 8, 2018